Galecto, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Amit Munshi. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Amit Munshi has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IKT / Inhibikase Therapeutics, Inc. Director 57,265
US:ZURA / Zura Bio Limited Director 777,384
US:ARNA / Arena Pharmaceuticals Inc President and CEO, Director 0
US:PULM / Pulmatrix, Inc. Director 15,000
US:GLTO / Galecto, Inc. Director 0
US:EPRS / EPIRUS Biopharmaceuticals, Inc. Chief Executive Officer, Director 29,661
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Amit Munshi. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases GLTO / Galecto, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GLTO / Galecto, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GLTO / Galecto, Inc. Insider Trades
Insider Sales GLTO / Galecto, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GLTO / Galecto, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GLTO / Galecto, Inc. Insider Trades
Insider Purchases IKT / Inhibikase Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GLTO / Galecto, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-10-21 IKT Munshi Amit 365,000 1.3700 365,000 1.3700 500,050 57 3.9700 949,000 189.78

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IKT / Inhibikase Therapeutics, Inc. Insider Trades
Insider Sales IKT / Inhibikase Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GLTO / Galecto, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IKT / Inhibikase Therapeutics, Inc. Insider Trades
Insider Purchases PULM / Pulmatrix, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GLTO / Galecto, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PULM / Pulmatrix, Inc. Insider Trades
Insider Sales PULM / Pulmatrix, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GLTO / Galecto, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PULM / Pulmatrix, Inc. Insider Trades
Insider Purchases ZURA / Zura Bio Limited - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GLTO / Galecto, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-04-22 ZURA Munshi Amit 159,744 3.1300 159,744 3.1300 499,999 25 6.0500 466,453 93.29
2023-06-05 ZURA Munshi Amit 117,647 4.2500 117,647 4.2500 500,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ZURA / Zura Bio Limited Insider Trades
Insider Sales ZURA / Zura Bio Limited - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GLTO / Galecto, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ZURA / Zura Bio Limited Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Amit Munshi as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-28 2025-02-21 4 IKT Inhibikase Therapeutics, Inc.
Common Stock
A - Award 57,265 57,265
2024-10-23 2024-10-21 4 IKT Inhibikase Therapeutics, Inc.
Common Stock
P - Purchase 365,000 365,000 1.37 500,050 500,050
2024-09-06 2024-04-22 4/A ZURA Zura Bio Ltd
Class A ordinary shares
A - Award 159,744 777,384 25.86 3.13 499,999 2,433,212
2024-04-24 2024-04-22 4 ZURA Zura Bio Ltd
Class A ordinary shares
P - Purchase 159,744 777,384 25.86 3.13 499,999 2,433,212
2023-06-05 2023-06-05 4 ZURA Zura Bio Ltd
Class A Ordinary Shares
P - Purchase 117,647 617,640 23.53 4.25 500,000 2,624,970
2023-03-21 3 ZURA Zura Bio Ltd
Class A Ordinary Shares
499,993
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Performance Restricted Stock Unit
D - Sale to Issuer -42,000 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
D - Sale to Issuer -168,000 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
D - Sale to Issuer -270,000 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
D - Sale to Issuer -285,000 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
D - Sale to Issuer -310,000 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
D - Sale to Issuer -56,861 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
D - Sale to Issuer -138,139 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
J - Other -85,847 0 -100.00
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
J - Other -28,800 85,847 -25.12
2022-03-11 2022-03-11 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
J - Other -250 114,647 -0.22
2022-03-11 2022-03-08 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
G - Gift -10,500 114,897 -8.37 98.51 -1,034,355 11,318,503
2022-01-05 2022-01-03 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
A - Award 85,847 125,397 217.06
2021-08-17 2021-08-16 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
P - Purchase 1,000 39,550 2.59 48.19 48,190 1,905,914
2021-08-13 2021-08-12 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
P - Purchase 1,000 38,550 2.66 50.41 50,410 1,943,306
2021-08-11 2021-08-10 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
P - Purchase 1,000 37,550 2.74 52.92 52,915 1,986,958
2021-03-03 2021-03-01 4 ARNA ARENA PHARMACEUTICALS INC
Employee Performance Restricted Stock Unit
A - Award 42,000 42,000
2021-03-03 2021-03-01 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 168,000 168,000
2021-03-03 2021-03-01 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
A - Award 28,800 36,550 371.61
2021-02-01 2021-01-28 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2021-01-20 2021-01-19 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -50,000 138,139 -26.58
2021-01-20 2021-01-19 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -50,000 7,750 -86.58 80.14 -4,006,760 621,048
2021-01-20 2021-01-19 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 50,000 57,750 645.16 15.50 775,000 895,125
2021-01-20 2021-01-15 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -50,000 188,139 -21.00
2021-01-20 2021-01-15 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -2,900 7,750 -27.23 81.06 -235,060 628,176
2021-01-20 2021-01-15 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -47,100 10,650 -81.56 80.19 -3,776,916 854,016
2021-01-20 2021-01-15 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 50,000 57,750 645.16 15.50 775,000 895,125
2021-01-14 2021-01-12 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -5,396 7,750 -41.05 75.64 -408,157 586,215
2021-01-14 2021-01-12 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -7,481 13,146 -36.27 75.07 -561,602 986,877
2021-01-14 2021-01-12 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -2,000 20,627 -8.84 73.90 -147,810 1,524,434
2021-01-11 2021-01-07 4 ARNA ARENA PHARMACEUTICALS INC
Performance Restricted Stock Unit
M - Exercise -23,400 0 -100.00
2021-01-11 2021-01-07 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
F - Taxes -8,523 22,627 -27.36 77.59 -661,300 1,755,629
2021-01-11 2021-01-07 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise 23,400 31,150 301.94
2020-12-09 2020-12-08 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -6,517 7,750 -45.68 70.00 -456,198 542,510
2020-11-30 2020-11-25 4 ARNA ARENA PHARMACEUTICALS INC
Performance Restricted Stock Unit
M - Exercise -11,700 23,400 -33.33
2020-11-30 2020-11-25 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
F - Taxes -5,183 14,267 -26.65 65.50 -339,486 934,488
2020-11-30 2020-11-25 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise 11,700 19,450 150.97
2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series D Preferred Stock
C - Conversion -1,844 0 -100.00
2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Common Stock
C - Conversion 4,793 4,793
2020-11-04 2020-09-25 4 GLTO Galecto, Inc.
Series D Preferred Stock
A - Award 1,844 1,844 27.11 49,991 49,991
2020-11-04 2020-06-24 4 GLTO Galecto, Inc.
Stock Option (right to buy)
A - Award 109,187 109,187
2020-08-31 2020-08-31 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -50,000 238,139 -17.35
2020-08-31 2020-08-31 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -50,000 7,750 -86.58 70.10 -3,505,035 543,280
2020-08-31 2020-08-31 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 50,000 57,750 645.16 15.50 775,000 895,125
2020-08-31 2020-08-28 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -50,000 288,139 -14.79
2020-08-31 2020-08-28 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -50,000 7,750 -86.58 70.00 -3,500,000 542,500
2020-08-31 2020-08-28 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 50,000 57,750 645.16 15.50 775,000 895,125
2020-06-04 2020-06-03 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -41,861 338,139 -11.02
2020-06-04 2020-06-03 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -8,139 56,861 -12.52
2020-06-04 2020-06-03 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -17,962 7,750 -69.86 69.26 -1,244,014 536,750
2020-06-04 2020-06-03 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -20,028 25,712 -43.79 68.61 -1,374,213 1,764,219
2020-06-04 2020-06-03 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -12,010 45,740 -20.80 67.36 -809,009 3,081,106
2020-06-04 2020-06-03 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 41,861 57,750 263.46 15.50 648,846 895,125
2020-06-04 2020-06-03 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 8,139 15,889 105.02 14.60 118,829 231,979
2020-06-04 2020-06-02 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -50,000 65,000 -43.48
2020-06-04 2020-06-02 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -50,000 7,750 -86.58 65.00 -3,250,000 503,750
2020-06-04 2020-06-02 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 50,000 57,750 645.16 14.60 730,000 843,150
2020-05-22 2020-05-22 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -34,800 115,000 -23.23
2020-05-22 2020-05-22 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -6,462 7,750 -45.47 59.12 -382,017 458,160
2020-05-22 2020-05-22 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -13,931 14,212 -49.50 58.61 -816,461 832,930
2020-05-22 2020-05-22 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -9,017 28,143 -24.27 57.52 -518,662 1,618,799
2020-05-22 2020-05-22 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -5,390 37,160 -12.67 56.67 -305,468 2,105,972
2020-05-22 2020-05-22 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 34,800 42,550 449.03 14.60 508,080 621,230
2020-05-22 2020-05-21 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise X -50,000 149,800 -25.03
2020-05-22 2020-05-21 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -50,000 7,750 -86.58 55.00 -2,750,000 426,250
2020-05-22 2020-05-21 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise X 50,000 57,750 645.16 14.60 730,000 843,150
2020-04-03 2020-04-02 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2020-03-03 2020-03-01 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 270,000 270,000
2020-02-14 2020-02-13 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise -15,200 199,800 -7.07
2020-02-14 2020-02-13 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -15,200 7,750 -66.23 55.00 -836,000 426,250
2020-02-14 2020-02-13 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise 15,200 22,950 196.13 14.60 221,920 335,070
2020-02-07 2020-02-05 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
S - Sale X -7,129 7,750 -47.91 50.00 -356,450 387,500
2020-01-13 2020-01-09 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2019-10-16 2019-10-14 4 ARNA ARENA PHARMACEUTICALS INC
Performance Restricted Stock Unit
M - Exercise -11,700 35,100 -25.00
2019-10-16 2019-10-14 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
F - Taxes -4,571 14,879 -23.50 47.32 -216,300 704,074
2019-10-16 2019-10-14 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
M - Exercise 11,700 19,450 150.97
2019-05-20 2019-05-16 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2019-01-08 2019-01-04 4 ARNA ARENA PHARMACEUTICALS INC
Employee Performance Restricted Stock Unit
A - Award 23,400 23,400
2019-01-08 2019-01-04 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 285,000 285,000
2018-06-06 2018-06-05 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 124,000 124,000
2018-01-22 2018-01-19 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 310,000 310,000
2017-06-15 2017-06-13 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 8,800 8,800
2017-05-15 2017-05-12 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
P - Purchase 25,000 76,875 48.19 1.19 29,750 91,481
2017-04-27 2017-04-26 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
P - Purchase 50,000 51,875 2,666.67 1.41 70,500 73,144
2017-04-27 2017-03-31 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
J - Other 625 1,875 50.00 1.24 775 2,325
2017-02-14 2017-02-13 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 2,150,000 2,150,000
2017-02-14 2016-12-30 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
J - Other 625 1,250 100.00 1.21 756 1,512
2017-02-14 2016-09-30 4 ARNA ARENA PHARMACEUTICALS INC
Common Stock
J - Other 625 625 1.41 881 881
2016-05-11 2016-05-11 4 ARNA ARENA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 3,800,000 3,800,000
2016-03-01 2016-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -9,887 29,661 -25.00
2016-03-01 2016-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -1,519 0 -100.00
2016-03-01 2016-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
F - Taxes -4,305 177,083 -2.37 2.80 -12,054 495,832
2016-03-01 2016-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
M - Exercise 9,887 181,388 5.76
2016-03-01 2016-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
M - Exercise 1,519 171,501 0.89
2015-12-17 2015-12-16 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
P - Purchase 8,270 169,982 5.11 2.80 23,156 475,950
2015-12-16 2015-12-15 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
P - Purchase 8,069 161,712 5.25 2.87 23,158 464,113
2015-12-10 2015-12-09 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
P - Purchase 13,190 153,643 9.39 4.07 53,683 625,327
2015-11-03 2015-11-02 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 199,537 199,537
2015-09-22 2015-09-21 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
P - Purchase 10,000 140,453 7.67 6.19 61,900 869,404
2015-09-21 2015-09-18 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
P - Purchase 10,000 130,453 8.30 5.99 59,860 780,892
2015-07-06 2015-07-02 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -22,681 14,860 -60.42
2015-07-06 2015-07-02 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,246 18,639 -27.99
2015-07-06 2015-07-02 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -21,273 43,397 -32.89
2015-07-06 2015-07-02 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
M - Exercise 51,200 120,453 73.93 1.00 51,200 120,453
2015-03-02 2015-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
A - Award 39,548 39,548
2015-03-02 2015-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
A - Award 1,519 1,519
2015-03-02 2015-02-27 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 301,225 301,225
2014-07-17 2014-07-15 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 332,694 332,694
2014-07-17 2014-07-15 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 37,541 37,541
2014-07-17 2014-07-15 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 25,885 25,885
2014-07-17 2014-07-15 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
A - Award 64,670 64,670
2014-07-17 2014-07-15 4 EPRS EPIRUS Biopharmaceuticals, Inc.
Common Stock
A - Award 69,253 69,253
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)